# Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

> **NCT05507450** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1271 (actual)

## Conditions studied

- Dengue Disease
- Dengue Virus

## Interventions

- **BIOLOGICAL:** V181 High-Potency Level
- **BIOLOGICAL:** V181 Mid-Potency Level
- **BIOLOGICAL:** V181 Low-Potency Level
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05507450
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-07
- **Primary completion:** 2023-06-05
- **Final completion:** 2024-05-07
- **Target enrollment:** 1271 (ACTUAL)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507450, "Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05507450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*